DICE Therapeutics
Dr. Jacobsen currently serves as the Chief Scientific Officer. He joined DICE Therapeutics in November 2015, initially serving as Vice President of Chemistry, and has led the Drug Discovery group since 2019. Prior to DICE Therapeutics, Dr. Jacobsen was at Theravance Biopharma (formerly Theravance, Inc.) for 18 years, most recently serving as Senior Director of Medicinal Chemistry. At Theravance, Dr. Jacobsen led three research programs in respiratory disease and helped transition six compounds into early development. As a member of the Theravance-GlaxoSmithKline Joint Project Committee (JPC), he helped advance collaboration assets through clinical trials to FDA approvals of Breo® and Anoro®. Within the medicinal chemistry department, he had line-management responsibility for several medicinal chemistry teams, as well as the high-throughput purification group and had a leadership role in the selection of new research projects.
Dr. Jacobsen received an A.B. in Chemistry from Harvard College, a Ph.D. in Organic Chemistry from the University of California, Berkeley, and completed postdoctoral work at Stanford University.
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.